Heavily-shorted Questcor (QCOR +6.1%) surges after receiving more positive sell-side commentary...
Heavily-shorted Questcor (QCOR +6.1%) surges after receiving more positive sell-side commentary (previous), this time from Jefferies, which is upgrading shares to Buy. Analyst Biren Amin believes investors are pricing Questcor as if almost no insurers will provide coverage for its Acthar gel for treating nephrotic syndrome or MS, something he considers unrealistic.
From other sites
at Nasdaq.com (Apr 9, 2015)
at Zacks.com (Mar 24, 2015)
at Zacks.com (Mar 6, 2015)
at Nasdaq.com (Mar 3, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs